Enanta Pharmaceuticals, Inc. Elects Yujiro S. Hata as Independent Director
August 23, 2021 at 09:02 pm
Share
The Board of Directors of Enanta Pharmaceuticals, Inc. has elected Yujiro S. Hata to serve as an independent director of the company in the class of directors whose term expires at Enanta’s 2024 annual meeting of stockholders. This election, which was effective on August 19, 2021, increases the number of directors to seven. The Board of Directors also appointed Mr. Hata to be a member of the Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors. Mr. Hata will receive the standard cash compensation for non-employee directors of Enanta, including retainer fees for Board and committee service. Mr. Hata will also have the benefit of Enanta’s standard form of indemnification agreement for non-employee directors.
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).